Rheumatologist Explains Why Mallinckrodt's Acthar Is A Winner
April 20, 2016 at 13:35 PM EDT
Piper Jaffray reiterated its Overweight rating and $97 target price on Mallinckrodt PLC (NYSE: MNK) after a Rheumatologist gave ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.